Skyrizi (Risankizumab)

Brand names:Skyrizi
Medication

What people taking Skyrizi (Risankizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Skyrizi (Risankizumab) for Psoriasis?

NameHow it went

About Skyrizi (Risankizumab)

What It's For

Risankizumab, sold as Skyrizi, is a prescription biologic: a laboratory-made antibody that calms one specific part of the immune system. It treats four long-term inflammatory conditions. In adults and children 6 and older, it is used for moderate to severe plaque psoriasis when the skin disease is extensive enough to need whole-body treatment or light therapy (phototherapy), and for active psoriatic arthritis, the joint inflammation that affects some people with psoriasis. In adults, it is also used for moderately to severely active Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease. For psoriasis, that typically means disease too widespread or stubborn for creams alone. It is not approved for children with Crohn's disease or ulcerative colitis.

How It Works

In these conditions, the immune system keeps sending inflammatory signals to the skin, joints or gut even when there is no infection to fight. One of the main signals keeping that inflammation going is interleukin-23 (IL-23), a messenger protein that sustains a group of immune cells driving psoriasis plaques and gut inflammation. Risankizumab attaches to IL-23 and stops it from reaching its receptor, so those cells release fewer of the chemicals that cause redness, scaling, joint swelling or bowel damage. Because it targets only IL-23, it acts more narrowly than ustekinumab (Stelara), an older biologic that blocks IL-23 together with a related messenger, interleukin-12. Calming this pathway takes weeks to show up as visible healing, and it can also make the body somewhat less able to fight certain infections.

Dosage & Administration

How Skyrizi is given depends on the condition. For plaque psoriasis and psoriatic arthritis, it is an injection under the skin with a prefilled pen or syringe, given at the start, again four weeks later, and then every 12 weeks. Adults can learn to inject themselves after training from a health professional; for children, an adult gives or supervises the injection, and children under 40 kg (about 88 pounds) receive a smaller dose. For Crohn's disease and ulcerative colitis, treatment begins with three starter doses given through a vein (intravenous infusions) at a clinic or infusion center, four weeks apart. From week 12, maintenance doses are injected under the skin every 8 weeks, either with a wearable on-body injector that attaches to the skin while it delivers the dose, or with prefilled syringes. Skyrizi is stored in the refrigerator and allowed to reach room temperature before injecting. Avoid injecting into skin that is tender, bruised, red, hardened or affected by psoriasis. If a dose is missed, give it as soon as you remember and then return to the regular schedule.

Side Effects

Most people tolerate Skyrizi well. The most common side effects are colds and other upper respiratory infections, headache, tiredness, redness or soreness at the injection site, and fungal skin infections such as athlete's foot. People treated for Crohn's disease or ulcerative colitis may also notice joint pain, abdominal pain, fever, back pain or rash, and some develop anemia (low red blood cells) or urinary tract infections. Because Skyrizi dampens part of the immune response, infections deserve attention. Contact the care team promptly about fever, sweats or chills, a cough or shortness of breath that will not settle, warm, red or painful skin, or burning when urinating. A dose may be postponed until an infection clears. In people treated for Crohn's disease or ulcerative colitis, Skyrizi has rarely caused liver injury, mainly during the first 12 weeks. Yellowing of the skin or eyes, dark urine, an unexplained rash, or nausea, vomiting, stomach pain and loss of appetite without another explanation needs prompt medical attention, so contact the care team right away. Serious allergic reactions are rare. Swelling of the face, lips, tongue or throat, trouble breathing or fainting after a dose is an emergency: call 911.

Interactions & Warnings

Before starting, the care team checks for active infections and for tuberculosis (TB). Skyrizi is not given to someone with active TB, and people with a hidden (latent) TB infection may need TB treatment first. People with frequent or long-lasting infections should discuss whether the benefits outweigh the risk. Anyone allergic to risankizumab or its ingredients should not use it. Vaccinations should be brought up to date before treatment begins. Live vaccines (those made with a weakened form of the virus or bacterium) should be avoided shortly before, during and shortly after treatment. Tell any clinician giving a vaccine that you take Skyrizi. For Crohn's disease and ulcerative colitis, liver tests are taken before the first infusion, and other treatments may be preferred for someone with cirrhosis (advanced liver scarring). There is too little information to know whether Skyrizi affects a pregnancy. Antibody medicines like it can cross the placenta, especially late in pregnancy, so a baby exposed in the womb may carry the drug for a time after birth, and its immune system could be affected. Anyone pregnant, planning pregnancy or breastfeeding should weigh this with their care team, keeping in mind that uncontrolled bowel disease also carries risks in pregnancy.

What to Expect

Improvement builds over weeks rather than days. In psoriasis trials, about three in four adults had skin that was at least 90% clearer after 16 weeks, compared with very few on placebo, and responses often deepened over the first year. In Crohn's disease, some people feel better within the first month of infusions (in trials, responses appeared as early as week 4), and the treatment's effect is usually judged around week 12. In ulcerative colitis, about one in four people were in remission after the 12-week infusion phase, with better results in those who had not already tried other advanced treatments. Not everyone responds, and the care team may change course if there is little improvement. Skyrizi controls inflammation rather than curing these conditions, so it is generally continued long term while it is working. In a psoriasis trial, people who stopped were noticeably more likely to see their skin worsen within a year than those who kept going. Ongoing care includes regular visits to review response, watching for infections, and, for bowel disease, liver blood tests during the first months along with periodic disease checks such as blood, stool or colonoscopy results.

Questions to Ask Your Doctor

  1. 1.Why is Skyrizi a good fit for me compared with other biologics or pill treatments for my condition?
  2. 2.How will we judge whether it is working, and how long should we give it before considering a change?
  3. 3.Do I need TB testing, other tests or any vaccines before I start?
  4. 4.Which signs of infection or liver trouble should make me call you, and should I skip a dose if I am sick?
  5. 5.How would Skyrizi fit with pregnancy plans or breastfeeding?

Last reviewed • Oct 2026

Educational content, not medical advice.